130 related articles for article (PubMed ID: 8735617)
1. Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits.
Soma MR; Donetti E; Seregni R; Barberi L; Fumagalli R; Paoletti R; Catapano AL
Br J Pharmacol; 1996 May; 118(2):215-9. PubMed ID: 8735617
[TBL] [Abstract][Full Text] [Related]
2. Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury.
Soma MR; Donetti E; Parolini C; Barberi L; Paoletti R; Fumagalli R; Catapano AL
J Cardiovasc Pharmacol; 1994; 23 Suppl 5():S71-4. PubMed ID: 7609512
[TBL] [Abstract][Full Text] [Related]
3. Direct antiatherogenic activity of isradipine and lacidipine on neointimal lesions induced by perivascular manipulation in rabbits.
Donetti E; Fumagalli R; Paoletti R; Soma MR
Pharmacol Res; 1997 May; 35(5):417-22. PubMed ID: 9299204
[TBL] [Abstract][Full Text] [Related]
4. Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits.
Soma MR; Natali M; Donetti E; Baetta R; Farina P; Leonardi A; Comparato C; Barberi L; Catapano AL
Br J Pharmacol; 1998 Dec; 125(7):1471-6. PubMed ID: 9884075
[TBL] [Abstract][Full Text] [Related]
5. Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits.
Donetti E; Soma MR; Barberi L; Paoletti R; Fumagalli R; Roma P; Catapano AL
Atherosclerosis; 1998 Nov; 141(1):45-51. PubMed ID: 9863537
[TBL] [Abstract][Full Text] [Related]
6. The antiatherosclerotic effects of calcium antagonists.
Paoletti R; Bernini F; Corsini A; Soma MR
J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S6-10. PubMed ID: 8852538
[TBL] [Abstract][Full Text] [Related]
7. Anti-atherosclerotic activity of the calcium antagonist lacidipine in cholesterol-fed hamsters.
Cristofori P; Lanzoni A; Gaviraghi G; Turton J; Sbarbati A
Biomed Pharmacother; 2000 Mar; 54(2):93-9. PubMed ID: 10759293
[TBL] [Abstract][Full Text] [Related]
8. Lacidipine has antiatherosclerotic effects independent of its actions on lipid metabolism and blood pressure.
Anacak GY; Ustünes L; Dilsiz OY; Ergul A
Vascul Pharmacol; 2010; 53(5-6):193-9. PubMed ID: 20709189
[TBL] [Abstract][Full Text] [Related]
9. Endothelial dysfunction, hypertension and atherosclerosis. A review of the effects of lacidipine.
Haller H; Cosentino F; Lüscher TF
Drugs R D; 2002; 3(5):311-23. PubMed ID: 12455152
[TBL] [Abstract][Full Text] [Related]
10. The calcium-channel blocker lacidipine reduces the development of atherosclerotic lesions in the apoE-deficient mouse.
Cristofori P; Lanzoni A; Quartaroli M; Pastorino AM; Zancanaro C; Cominacini L; Gaviraghi G; Turton J
J Hypertens; 2000 Oct; 18(10):1429-36. PubMed ID: 11057430
[TBL] [Abstract][Full Text] [Related]
11. Effect of lacidipine on cholesterol esterification: in vivo and in vitro studies.
Bernini F; Canavesi M; Bernardini E; Scurati N; Bellosta S; Fumagalli R
Br J Pharmacol; 1997 Nov; 122(6):1209-15. PubMed ID: 9401788
[TBL] [Abstract][Full Text] [Related]
12. Involvement of the nitric oxide system in the anti-atherosclerotic potential of lacidipine in the ApoE-deficient mouse: a morphological, functional, and electrochemical study.
Cristofori PG; Crivellente FA; Faustinelli I; Lanzoni AR; Lazzarini C; Vecchiato E; Andreoli M; Turton JA; Zancanaro C; Crespi FM
Toxicol Pathol; 2004; 32(4):493-9. PubMed ID: 15223775
[TBL] [Abstract][Full Text] [Related]
13. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice treated with lacidipine is associated with a decreased susceptibility of low-density lipoprotein to oxidation.
Cristofori P; Crivellente F; Campagnola M; Pasini AF; Garbin U; Rigoni A; Tosetti M; Turton J; Faustinelli I; Cominacini L
Int J Exp Pathol; 2004 Apr; 85(2):105-14. PubMed ID: 15154916
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antiatherosclerotic effects of dihydropyridine calcium channel blocker and HMG-CoA reductase inhibitor on hypercholesterolemic rabbits.
Takayama M; Matsubara M; Arakawa E; Takada C; Ina Y; Hasegawa K; Yao K
Vascul Pharmacol; 2007 Apr; 46(4):302-8. PubMed ID: 17197250
[TBL] [Abstract][Full Text] [Related]
15. Lacidipine: a review of its use in the management of hypertension.
McCormack PL; Wagstaff AJ
Drugs; 2003; 63(21):2327-56. PubMed ID: 14524737
[TBL] [Abstract][Full Text] [Related]
16. Effects of lacidipine on experimental models of atherosclerosis.
Bernini F; Corsini A; Raiteri M; Soma MR; Paoletti R
J Hypertens Suppl; 1993 Mar; 11(1):S61-6. PubMed ID: 8483025
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of lacidipine, a vascular-selective calcium antagonist.
Micheli D; Ratti E; Toson G; Gaviraghi G
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S1-8. PubMed ID: 1725998
[TBL] [Abstract][Full Text] [Related]
18. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension.
Lee CR; Bryson HM
Drugs; 1994 Aug; 48(2):274-96. PubMed ID: 7527328
[TBL] [Abstract][Full Text] [Related]
19. The antiatherosclerotic effect of the calcium antagonists and their implications in hypertension.
Nayler WG; Panagiotopoulos S
Am Heart J; 1993 Feb; 125(2 Pt 2):626-9. PubMed ID: 8430608
[TBL] [Abstract][Full Text] [Related]
20. Felodipine inhibits intimal lesion formation in the hypercholesterolemic rabbit: differential effects on endothelial and monocyte determinants of atherogenesis.
Wang BY; Niebauer J; Singer AH; Tsao PS; Cooke JP
Vasc Med; 1996; 1(3):173-9. PubMed ID: 9546935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
